No services found
No Products found
100µg
IgG1
ProteoGenix
COVID-19 products
Monoclonal Antibody
The anti-CoV-Nucleoprotein (D2) antibody targets the nucleoprotein (protein N or nucleocapsid phosphoprotein) of the new pandemic strain of coronavirus, SARS-CoV-2. Protein N is one of the four structural proteins carried by SARS-CoV-2 which further includes the spike (S) glycoprotein, envelope (E) protein, and membrane protein (M). Unlike the other three structural proteins, protein N is confined to the intraviral domain of SARS-CoV-2 where it plays an important role plays in RNA packaging. Moreover, it is known to participate in the process of viral replication, assembly, and release. Recent studies show that the nucleoprotein forms dimers in SARS-CoV-2 with an estimated molecular weight of 114 kDa. And that it potently binds to non-specific nucleic acids (i.e. including host DNA/RNA molecules). Numerous studies show that protein N has a longer persistence than other structural proteins in the serum of COVID-19 infected patients. These results indicate that although anti-Nucleoprotein antibodies may find limited therapeutic applicability, they may be crucial for the design of sensitive and robust SARS-CoV-2 detection assays. The new antibody is a fully human IgG molecule developed by screening the vastly diverse COVID-19 human library (LiAb-SFCOVID-19™). The library gathers the immune diversity of dozens of COVID-19 patients and it is fully adapted to fast screening (i.e. biopanning) with robust phage display technologies. The specificity and high affinity of the new antibody were tested and validated through enzyme-linked immunosorbent assay (ELISA) using recombinant protein N as the desired target. Furthermore, the antibody showed great stability and ease of production in the high productivity transient mammalian system – XtenCHO™.
Anti-CoV-Nucleoprotein (D2) antibody, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Publication
Cerutti, H., Ricci, V., Tesi, G. et al. Large scale production and characterization of SARS-CoV-2 whole antigen for serological test development. J Clin Lab Anal. 2021; e23735. doi
Reviews
There are no reviews yet.
Your email address will not be published. Required fields are marked *
In which application did you use the antibody? * WB ELISA Sandwich ELISA IF IHC IP FC other
Did it work in your application? * Yes No
Your review *
Name *
Email *
Save my name, email, and website in this browser for the next time I comment.
Related products
Got a question or need a quote? Message us and we’ll get back to you 48 hours or less.
First name
Last name
Email address
Lab / Company
Phone number
send
Your cart is currently empty.